Soligenix's HyBryte(TM) Shows Promise in Rare Skin Cancer Treatment Study
May 1, 2025 — Soligenix advances rare disease treatment with HyBryte(TM) therapy for CTCL, showing promising results in a study. Learn more about the global market growth and the impact on patients.